On September 18 the FDA sent a warning letter to one of the biggest compounding pharmacies behind telehealth GLP-1 brands.
The finding was expected. The evidence it used was not: order volume, and clinical notes copied word for word.
The Pulse
The FDA called compounded GLP-1 personalization "pretextual."
The FDA's September 18 warning letter to Empower Pharmacy, the third the Houston compounder has received, found its tirzepatide-plus-niacinamide and semaglutide-plus-B12 products were essentially copies of Zepbound, Mounjaro, Ozempic and Wegovy.
The agency cited production volume as evidence that the "significant difference" behind those prescriptions was pretextual. It also flagged identical justification language across records, and tech platforms that hand prescribers pre-selected menu options.
That last point is about telehealth intake, not the pharmacy floor. More on it below.
700,000 seniors started a GLP-1 through Medicare in under three months.
Lilly CEO Dave Ricks told CNBC on September 21 that 700,000 new seniors have started GLP-1s since Medicare coverage launched in July, and 70% are on Lilly drugs. The temporary Bridge program sets the co-pay at $50 a month.
He also said Foundayo is taking a third of new oral GLP-1 starts.
Any cash-pay brand with a 65+ segment is now priced against $50 a month. Service is the only lever left for that cohort.
Martha Stewart's Foundayo ad says she doesn't take Foundayo.
A paid Lilly Instagram ad has Martha Stewart telling viewers to ask their doctor about the pill, with an on-screen line disclosing she does not take it. Legal experts quoted by HuffPost in mid-September said it meets FDA requirements. Plenty of her followers were less forgiving.
Manufacturers now market to consumers the way telehealth brands used to. Their disclosure standard is the one your patient stories will get measured against.
The Deep Dive
"Personalized" just got a definition, and the FDA measures it in volume.
When the shortage ended, most compounded GLP-1 brands stopped selling plain semaglutide. They started selling semaglutide plus B12, or tirzepatide plus niacinamide, with a note on each prescription explaining why this patient needs the difference.
The Empower letter shows what the FDA thinks of that model at scale.
1. The letter reached past the pharmacy and into your intake.
The FDA found three things in Empower's records:
Prescriptions with no significant-difference determination at all
The same justification repeated word for word across many records
High order volume for the same few products
Then it named the mechanism: third-party technology platforms that give prescribers pre-selected menu options for that justification.
Most telehealth prescribing tools were built to make that step fast. Fast and identical is now the exact pattern the FDA is describing.
If your intake ends with a provider clicking a dropdown, that sentence describes your stack. The pharmacy got the letter. The workflow that produced the prescriptions sits upstream of it.
2. Your lifecycle copy is part of the record.
Lilly and Novo have argued this same "pretext" theory in lawsuits against compounders and telehealth platforms. Now the FDA uses the word too.
In that kind of dispute, your emails are evidence. A welcome flow promising "a formulation built for you," sent to thousands of patients who all get the same SKU at the same dose, documents the gap between claim and practice better than a regulator could.
We read a lot of telehealth onboarding flows. "Personalized" shows up in almost all of them, and in most it describes the intake quiz, not the product.
3. Your pharmacy is a single point of failure in your retention.
Empower is now on its third warning letter. What any specific pharmacy does next is not public, and nobody should guess.
But if one pharmacy fills most of your active subscriptions, one response to one letter could change the product, the price or the ship date for most of your base in the same week. Every one of those patients hits a decision point at once, and that is exactly where patients decide whether to stay.
The brands that get through a supply change keep the patients who heard about it before the box looked different. The rest find out from their cancellation reasons.
The takeaway: treat "personalized" as a claim you have to prove patient by patient, in the chart and in the inbox. And know how much of your revenue runs through one pharmacy and one SKU before someone else's letter tells you.
Quick Takes
Hims gives away a scale. It's a retention device.
Taking apart the Hims funnel last month, the free smart scale at checkout stood out more than any ad.
It does three jobs: a checkout bonus, a daily habit sitting in the patient's bathroom, and a weight history that keeps growing inside the Hims app.
Leaving means losing that history, not just switching suppliers. When the molecule is the same everywhere, the moat has to be built from something else.
Segment the inbox provider, not the whole list.
If your overall open rate looks healthy but Gmail or Outlook is dragging, don't tighten the engagement window for everyone. Check the per-provider breakdown in your ESP.
If one provider sits well below the rest, give it its own tighter segment and leave everyone else at full reach. Shrinking every send to fix one mailbox provider throws away reach you never needed to lose.
One Thing to Try
Export your active subscriptions with two columns: product SKU and dispensing pharmacy.
Calculate the share of active revenue on your top SKU and the share running through your top pharmacy. If either is above half, draft the "your medication is changing" email now, while nothing is changing.
Then search your welcome and onboarding flows for "personalized," "custom" and "tailored." For each hit, ask whether it describes something that actually differs patient to patient, and if not, rewrite it around what does: provider review, dose adjustments, check-ins.
Takes under an hour. Much cheaper than hearing your own copy quoted back to you.
If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz
Reply to this with your biggest retention challenge. I read and respond to every single one.
